Objective. To record the correlation between color power Doppler sonographic measurement of breast tumor vasculature and immunohistochemical analysis of microvessel density for the quantitation of angiogenesis. Methods. Women with palpable breast masses scheduled for excision biopsy were scanned with two-and three-dimensional color power Doppler sonography before and after the administration of a sonographic contrast agent. Vessel counts were performed on two-and three-dimensional sonographic images before and after contrast agent administration. All tumors were surgically removed and underwent immunohistochemical analysis for microvessel density assessment. The sonographic measure of tumor vascularity was correlated with microvessel density. Results. Pathologic examination showed 43 breast cancers and 14 benign breast masses. Higher microvessel density was noted in malignant than benign breast masses (P < .0005). Color power Doppler sonographic measurement of tumor vessel number showed a significant positive correlation with tumor size (P < .05) and progesterone receptor negativity (P < .05). A significant positive correlation was observed between microvessel density and the number of intratumoral blood vessels assessed by both two-and three-dimensional color power Doppler sonography (P < .05). Regression models showed threedimensional color power Doppler sonography to have a significantly higher correlation with microvessel density when compared with two-dimensional color power Doppler sonography at baseline (P < .005). The administration of a sonographic contrast agent did not improve correlation with microvessel density. Conclusions. A significant correlation was shown between color power Doppler sonographic measurement of tumor vascularity and microvessel density by immunohistochemical analysis. Further improvement in Doppler sonographic techniques to map capillary vessel flow should be explored to improve the current association with pathologic findings.
ngiogenesis (also known as neovascularization) is the formation of new capillaries from the existing vascular network and is essential for all tumor growth and dissemination. 1 Tumors that have increased angiogenesis include breast cancer, hepatocellular carcinoma, thyroid carcinoma, melanoma, and renal cell carcinoma. Recent studies have shown that intratumoral microvessel density (MVD) is an important prognostic marker of survival in breast cancer 2, 3 and for prediction of the likelihood of systemic metastases. 4 More importantly, vascular density has been shown to decrease in responders to standard chemotherapy 5 and angiogenesis inhibitors. 6 In breast cancer, higher histologic capillary density has been found to correlate with a higher rate of recurrence, independent of other prognostic factors. 7 To date, there are no standard validated methods for direct measurement of tumor neovascularization. Tumor capillary density, measured as "vascular hot spots" after immunohistochemical (IHC) factor VIII-related or CD31 antigen staining, has been tested as an indicator of angiogenesis in paraffin-embedded specimens 7 and is the yardstick of angiogenesis measurements. These IHC methods are limited because of a random sampling error secondary to intratumoral heterogeneity and the invasiveness of repeated biopsies for the monitoring of response to therapy. 8, 9 Hence, it would be important to develop a simple and noninvasive in vivo technique to measure angiogenesis for the prediction of prognosis and for monitoring the response to systemic treatment by sequential repeated measurements.
So far, in vivo imaging techniques have focused on the use of contrast-enhanced magnetic resonance (MR) imaging for characterization of tumor microvasculature. The feasibility of contrast-enhanced MR imaging as a measure of angiogenesis has been explored by several techniques and has shown a correlation with histologic capillary density. [9] [10] [11] [12] Nonetheless, MR imaging is time-consuming, expensive, and impractical for routine application.
Although there have been reports on the correlation between Doppler sonography and tumor neovascularization, 13, 14 to the best of our knowledge, to date there are no studies in the literature reporting a correlation between pathologic MVD and two-dimensional (2D) and three-dimensional (3D) color power Doppler (CPD) sonography with a contrast agent. The aim of this study was to correlate CPD sonographic measurement of breast tumor vascularity with measurements from IHC analysis of MVD, both before and after administration of contrast material.
Materials and Methods

Study Population
Fifty-seven women age 19 to 87 years (mean, 52 years) with 57 breast masses who were scheduled for excision biopsy were recruited into the study. In vivo measurement of breast tumor vascularity was performed semiquantitatively by CPD sonography. All masses were surgically removed, and MVD by IHC analysis was assessed by a single pathologist (G.M.K.T.). This study received local ethics committee approval, and informed consent was obtained from all patients.
Imaging and CPD Sonography
Before histologic diagnosis, all women prospectively underwent sonography by 1 breast radiologist (W.T.Y.) who was blinded to the patient history. Gray scale sonography followed by CPD sonography was performed on the breast mass with a 5-to 12-MHz linear array transducer with a 6-MHz Doppler operating frequency on an HDI 3000 or HDI 5000 unit (Philips Ultrasound, Bothell, WA). Optimized power angiographic parameters were set at a pulse repetition frequency of 750 to 1000 Hz, a low wall pass filter, medium persistence, high sensitivity, and the use of dynamic motion differentiation. Color power Doppler gain was optimized with an increase in gain until the color box was filled with uniform low-level blue noise with a minimal yellow power signal detected (≈75%-85% gain). [15] [16] [17] Twodimensional color power Doppler sonography was performed, followed by 3D CPD cine loop imaging. Acquisition involved capturing frames of CPD images over 10 seconds at a medium slice thickness (7 slices). The linear array transducer was swept slowly across the tumor mass with a steady pace and constant light pressure to avoid inadvertent compression of vessels and a possible flash artifact. Images were obtained before and after injection of a microbubble echo enhancer. A first-generation galactose-based contrast agent, SH U 508A (Levovist; Schering AG, Berlin, Germany), which contains microbubbles that are maintained during passage through the pulmonary vascular system, was adminis-A tered to provide systemic enhancement. 18, 19 The recommended dose of 10 mL of contrast agent at a concentration of 300 mg/mL galactose was injected as a bolus at approximately 2 mL/s via a 19-gauge plastic cannula inserted into the brachial vein and flushed with 10 mL of saline. For evaluation of the contrast agent, the video recording was started 30 seconds before the injection and continued for 5 minutes or the time when the signal intensity of the CPD sonographic signal was judged subjectively to return to the baseline level.
Image Acquisition and Evaluation (Vessel Counts)
The most vascular regions of each tumor were captured on hard copy laser images and magneto-optical disks as well as recorded on videotape for each lesion in 2D and 3D displays both before and after contrast agent administration. For each breast mass, CPD sonographic interrogation was performed, and the number and pattern of vessels were noted. The vessel distribution was subjectively assessed according to modified previously published criteria 20 as follows: (1) peripheral vessels, 1 or more blood vessels along the margin of a mass with minimal branching; (2) central vessels, persistent focal color flow signal within the lesion, not extending to the margins and without substantial branching; and (3) side-branching vessels, persistent reproducible color flow signals that branched from any peripheral or central vessel.
Pathologic Examination
Routine histologic analysis of breast tumors was assessed with hematoxylin-eosin stains. For all cancers, the histologic types were classified according to World Health Organization criteria. Tumor grading was performed according to modified previously published criteria. 
Pathologic Estimation of MVD
For intratumoral MVD, one 4-µm section that included the most representative part of the lesion (Fig. 1A) was selected for staining with CD31 (1:50, DakoCytomation Denmark A/S) by the standard avidin-biotin method. The stained section was initially scanned at low power to pick up the hot spots with a higher density of CD31-positive cells within the tumor, and 5 high-power fields (×400; field area, 0.19 mm 2 ) were counted. All positively stained discrete cells or cell clusters with or without visible lumina were counted as 1 microvessel (Fig. 1B) . Figure 1 . A, Photomicrograph of invasive ductal carcinoma (hematoxylin-eosin, original magnification ×100). B, CD31 IHC analysis of the same breast specimen (original magnification ×400). All dark areas are CD31-positive vascular structures.
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Statistical Analysis
The data obtained with 2D and 3D CPD sonography and MVD were compared with the final histologic findings. Pathologic size, nodal status, histologic type, histologic grade, and hormonal receptor status were assessed for all breast cancers. Clinicopathologic correlation with MVD and sonographic measurements of tumor vessel number was evaluated by a 2-sample t test.
Pearson correlation coefficients were computed between pathologic MVD and sonographic measurement of breast tumor vascularity. Regression models were used to study differences in correlation between 2D and 3D and between precontrast and postcontrast CPD sonography.
Results
A total of 57 breast masses (43 malignant and 14 benign) were studied. Table 1 ). Mean 2D precontrast, 3D precontrast, and 3D postcontrast CPD sonographic measurements of tumor vessel number were significantly higher in malignant than in benign masses (P < .005, .0005, and .05, respectively; Table 1 ).
There was no association between MVD and clinicopathologic parameters (Table 2) . Color power Doppler sonographic measurement of tumor vessel number showed a significant positive correlation with pathologic size (all P < .05) and a negative correlation with PR (all P < .05; Table 3 ).
For all breast masses, a significant correlation was expressed between MVD and CPD sonographic measurements of tumor vessel number (P < .05) both at baseline and after contrast agent administration ( Table 4 ). The scatterplots between 2D and 3D CPD sonography before and after contrast agent administration are shown in Figures 2 and 3 . Regression models showed a significantly higher R 2 value for 3D compared with 2D CPD sonography at baseline (P = 0.005; Table 5 ). Contrast agent administration did not improve the correlation with MVD.
Discussion
Breast cancer is the most common female malignancy and is ideally suited for Doppler sonography because of its superficial location and easy penetrability with the transducer, making it a suitable model for the study of in vivo angiogenesis. This neovascularization penetrates the lesion from its periphery and consists of thinwalled blood vessels that lack a muscular layer and often show chaotic anastomoses and shunts. [22] [23] [24] The multiplicity of vessels, their disordered pattern, and the arteriovenous shunts of these tumor vessels give rise to flow that can be detected as high-velocity signals with a distinctive rasping sound on continuous wave or pulsed Doppler sonography. 25 These "tumor flow signals" have been detected in carcinomas in the breast and thyroid as well as in primary hepatocellular and renal cell carcinomas. [26] [27] [28] [29] Recent developments with the use of color Doppler and CPD sonography have shown a predictive value of tumoral color Doppler signals in determining the nature of breast lesions. 20, [30] [31] [32] [33] [34] [35] The clinical role of Doppler sonography in breast cancer discrimination is not fully accepted, however. Wilkens et al 36 gave a balanced summary of the mixed but generally positive results with color flow imaging in the breast as of 1998. These methods have been further explored with the addition of microbubble sonographic contrast agents. The use of contrast-enhanced sonography increased the sensitivity and specificity to 100% in differentiating the vascularity between benign and malignant primary breast lesions. 37 The microbubble sonographic contrast agent Levovist consists of specially manufactured galactose microparticles for suspension in sterile water. It acts as a dose-dependent acoustic scatterer because of the multiple interfaces between the microbubbles and the surrounding fluid. These microbubbles are less than 4 µm in diameter and can therefore cross the lung bed and increase the echogenicity of blood by 10 to 20 dB, thereby enhancing the signal-noise ratio in color Doppler imaging. Levovist also contains a trace of palmitic acid, which improves the intravascular stability of the microbubbles, thereby providing a prolonged effectual blood pool-enhancing agent for an average duration of 6 min. By this mechanism, sonographic imaging with contrast enhancement provides a reliable measurement of blood pool vascularity of tumors. This report shows significantly higher MVD and CPD sonographic measurements of tumor vessel number in malignant compared with benign breast masses, reinforcing the potential of sonography in differentiating between malignant and benign breast disease. Although a previous report showed no significant correlation between MVD and intratumoral blood flow velocity assessed by color-coded Doppler imaging, 14 the results of this study show a weak but significant correlation between CPD sonograph- ic measurement of the tumor vessel number and pathologic MVD in breast tumors. Color power Doppler sonography is 3 to 5 times more sensitive than color Doppler sonography in the detection of flow signals, because it measures the total integrated Doppler power spectrum, thereby imaging the amplitude of blood flow rather than the direction or velocity, as in conventional color or pulsed Doppler sonography. 15, 16 This suggests that high-frequency sonographic studies of angiogenesis may best be directed at the vessel number and morphology rather than blood flow velocity, because velocity indices at current levels of transducer sensitivity and equipment technology may not accurately reflect the pathophysiologic characteristics of angiogenesis. Correlation with MVD was significantly higher with 3D than with 2D CPD sonography. Three-dimensional sonography permits a more global perspective of tumor vessel morphologic characteristics, thus permitting greater accuracy of vessel mapping and improved association with tumor angiogenesis. This can potentially contribute to breast cancer treatment, particularly in the evaluation of the response to medical therapy with antiangiogenic agents.
Previous studies have shown no association between MVD and conventional prognostic indicators, including lymph node status and lesion size. 10, 14, 38 CPD sonographic vascularity, however, showed a significant positive correlation with lesion size and PR negativity in this study. The exact reasons for these heterogeneous findings are not clear, but this preliminary positive correlation between sonographic measurement of the tumor vessel number and tumor biological characteristics may increase the role of sonography in prognostication of breast disease, with the potential that CPD sonographic vascularity may become an independent prognostic marker. 
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Interestingly, the administration of the sonographic contrast agent did not improve the correlation with MVD. This may be related to a limitation known as the "blooming" artifact that occurs after administration of current contrast agents. This artifact appears as excessive contrast enhancement beyond the anatomic boundaries of vessels, which may impede vessel count. Newer contrast agents are being developed together with improved Doppler techniques, including contrast-enhanced harmonic and pulse inversion imaging, which have been extensively investigated in the interrogation of liver lesions by lower-frequency transducers. [39] [40] [41] [42] This technique improves lateral resolution and increases the signal-noise ratio, thus decreasing image-degrading noise and flash artifacts when compared with the conventional power Doppler model. Therefore, these new and specially developed techniques may open a highway for improved small-vessel flow imaging.
These preliminary results encourage the continued development of sonographic techniques for mapping and depiction of tumor vascularity. If successful, this technique may serve as a means for correlation of vessel density, prognosis, and possibly treatment response and thus may provide a new and useful method for assigning individual patients to appropriate therapeutic regimens. Although a positive correlation was not obtained in this small study between MVD and prognosis, many reports in the literature suggest that a strong positive correlation between MVD and sonography will be applicable for predicting the prognosis and response to standard systemic treatment and antiangiogenic agents, not only for breast cancer but also for a wide range of other malignancies, notably hepatocellular carcinoma, melanoma, and renal cell carcinoma. Sonography can be further used to study variation in angiogenesis between different metastatic sites (e.g., liver metastases and nodal involvement) and possibly to give valuable insight into understanding the biological mechanisms behind tumor resistance to systemic therapy. 
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